Researcher
Matthias D'Huyvetter
- Keywords:Medicine
- Disciplines:Engineering and technology, Agricultural, veterinary and food sciences, Social sciences, Medical and health sciences
Affiliations
- Medical Imaging (Research group)
Member
From20 Oct 2010 → Today - Supporting clinical sciences (Department)
Member
From1 Oct 2021 → Today - Supporting clinical sciences (Department)
Member
From8 Apr 2019 → 31 Dec 2022 - Supporting clinical sciences (Department)
Member
From8 Apr 2019 → 31 Dec 2020 - Supporting clinical sciences (Department)
Member
From1 Jan 2017 → 20 Oct 2022 - Supporting clinical sciences (Department)
Member
From1 Jan 2014 → 20 Oct 2022 - Medical Imaging and Physical Sciences (Department)
Member
From1 Sep 2009 → 31 Dec 2013
Projects
1 - 8 of 8
- Research on radioactive nuclei at ISOLDE-CERN, SPIRAL2- GANIL and MEDICIS-CERNFrom1 Jan 2023 → TodayFunding: FWO International research infrastructure (IRI)
- Evaluation of an in vivo pre-targeting approach for targeted radionuclide therapy of cancer using clickable anti-B7-H3 single domain antibodies.From1 Nov 2021 → TodayFunding: FWO fellowships
- Combining targeted radionuclide therapy and cancer immunotherapy to advance precision medicine through innovation.From1 Nov 2019 → 31 Oct 2023Funding: FWO fellowships
- Visiting Polish researcher prof. Magdalena Rodak (22-28 september 2019)From22 Sep 2019 → 28 Sep 2019Funding: International Cooperation and Mobility
- Visiting Polish researcher prof. Marek Pruszynski (22 - 28 september 2019)From22 Sep 2019 → 28 Sep 2019Funding: International Cooperation and Mobility
- SRP-Groeifinanciering: Single-domain antibody fragment (SdAb)-based TArgeted Radionuclide Therapy: STaRT programmeFrom1 Mar 2019 → TodayFunding: BOF - projects
- Nanobody-based theranostics in cancer therapy.From1 Oct 2015 → 30 Sep 2021Funding: FWO fellowships
- Molecular imaging of HER2 expression of breast carcinoma with radiolabeled NanobodiesFrom1 Jan 2009 → 31 Dec 2010Funding: FWO research project (including WEAVE projects)
Publications
1 - 10 of 36
- Case Study #3: Antibody Fragments in Radiopharmaceutical Therapy(2023)
Authors: Cyprine Neba Funeh, Parinaz Asiabi, Matthias D'Huyvetter, Nick Devoogdt
Pages: 253-273Number of pages: 20 - Optimized cyclotron production of 211At: The challenge of 210Po-characterization(2023)
Authors: Matthijs B Sevenois, Brian WM Miller, Holger Jan Jensen, Matthias D'Huyvetter, Peter Covens
- Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy(2023)
Authors: Cyprine Neba Funeh, Nick Devoogdt, Dora Mugoli Chigoho, Timo De Groof, Jessica Bridoux, Thomas Ertveldt, Peter Covens, Matthias D'Huyvetter
- Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment(2023)
Authors: Thomas Ertveldt, Ahmet Krasniqi, Hannelore Ceuppens, Janik Puttemans, Yana Dekempeneer, Kevin De Jonghe, Wout de Mey, Quentin Lecocq, Yannick De Vlaeminck, Robin Maximilian Awad, et al.
Pages: 751-758 - A realistic multiregion mouse kidney dosimetry model to support the preclinical evaluation of potential nephrotoxicity of radiopharmaceutical therapy(2023)
Authors: Clarita Saldarriaga Vargas, Lara Struelens, Matthias D'Huyvetter, Vicky Caveliers, Peter Covens
Pages: 493-499 - Radiolabeled single-domain antibodies as a means to evoke and monitor immunological responses in malignant lesions(2023)
Authors: Thomas Ertveldt, Karine Breckpot, Matthias D'Huyvetter, Marleen Keyaerts, Nick Devoogdt
Number of pages: 177 - Preclinical evaluation of 225Ac-labeled single-domain antibody for the treatment of HER2pos cancer(2022)
Authors: Magdalena Rodak, Yana Dekempeneer, Maria Wojewódzka, Vicky Caveliers, Peter Covens, Brian W Miller, Matthijs B Sevenois, Frank Bruchertseifer, Alfred Morgenstern, Tony Lahoutte, et al.
Pages: 1835-1845 - Assessment of mouse-specific pharmacokinetics in kidneys based on I-131 activity measurements using micro-SPECT(2022)
Authors: Clarita Saldarriaga Vargas, Lara Struelens, Matthias D'Huyvetter, Vicky Caveliers, Peter Covens
Pages: 13 - Radiotheranostic Agents in Hematological Malignancies(2022)
Authors: Jo Caers, Elodie Duray, Louise Vrancken, Guillaume Marcion, Valentina Bocuzzi, Kim De Veirman, Ahmet Krasniqi, Margaux Lejeune, Nadia Withofs, Nick Devoogdt, et al.
- Targeted radionuclide therapy with low and high-dose Lutetium-177 labeled single domain antibodies induces distinct immune signatures in a mouse melanoma model(2022)
Authors: Thomas Ertveldt, Lien De Beck, Kirsten De Ridder, Hanne Locy, Wout de Mey, Cleo Goyvaerts, Quentin Lecocq, Hannelore Ceuppens, Yannick De Vlaeminck, Robin Maximilian Awad, et al.
Pages: 1136-1148
Patents
1 - 5 of 5
- Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer (Inventor)
- Radiolabelled antibody fragments for use in treating cancer (Inventor)
- Anti-cd38 single-domain antibodies in disease monitoring and treatment (Inventor)
- Anti-cd38 single-domain antibodies in disease monitoring and treatment (Inventor)
- Radiolabelled antibody fragments for use in treating cancer (Inventor)